“We’ve always been focused on giving our clients some of the industry’s best and most experienced individuals to oversee study execution. Rosemary is one of them. She’s a great addition to our CRO team, bringing over 20 years in the pharmaceutical industry,” commented Stephen J. Trevisan, President and CEO.
Mrs. McGlynn’s background includes a blend of large pharma and consulting firms, most recently working for Aerotek/Roche Pharmaceuticals. Her expertise covers a breadth of therapeutic indications and also includes eight years of clinical and management experience in Phase I through IV trials; complementing the knowledge of the existing CRO staff.
“I am excited to join a dynamic organization that can truly deliver a more productive way of executing clinical research,” said Mrs. McGlynn.
Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique system for delivering quality, on time, and cost effective clinical studies. Accelovance offers CRO services, clinical sites and a dedicated patient recruitment department with call center. In China, the Company operates through its wholly-owned foreign enterprise in Beijing as a contract research organization (CRO). Accelovance is focused on optimizing the quality and productivity of multiple clinical sites, through strong central management and targeted pro-active patient recruitment. Delivering high quality and timely clinical trial support services, Accelovance is committed to understanding and meeting its clients needs to contribute to their success.
For more information, visit the company’s website at http://www.accelovance.com.
CONTACT: Media: Garrett D. Smith at 240.238.4900
